McMaster researcher wins $50,000 ACE50 top prize to commercialize promising new antibiotic, plans spinout
Postdoctoral fellow Manoj Jangra won the Heersink ACE50 top prize of $50,000 on Nov. 16, 2026, for a pitch to commercialize lariocidins, a newly identified class of preclinical antibiotics from McMaster. The award will support formation of the planned Hamilton spinout Hammer Therapeutics and Jangra’s entry into a six-month Heersink ACE50 Fellowship to develop commercialization plans.
Manoj Jangra (Michael G. DeGroote Institute for Infectious Disease Research) secured the $50,000 Heersink ACE50 top prize on Nov. 16, 2026 for a pitch focused on advancing lariocidins — antibiotics discovered at McMaster. Funds are earmarked for company formation and branding for the planned spinout Hammer Therapeutics and to support hiring a postdoctoral or PhD trainee to de‑risk development. Jangra will join the six‑month Heersink ACE50 Fellowship for mentorship and commercialization coaching. Additional ACE50 faculty awards (several $25,000 and a $10,000 favourite prize) were also announced.
Read the original story · McMaster University — https://news.mcmaster.ca/pitch-to-commercialize-promising-antibiotic-earns-ace50-top-prize/